New Drugs and Perspectives in Treating Acute Heart Failure

Prof. Dr. med. Veselin Mitrovic
Kerckhoff-Klinik Forschungsgesellschaft, Bad Nauheim

Therapies for managing ADHF are far from ideal: Hospitalization rates and disease mortality continue to increase, whereas current pharmacotherapy has its limitations.

As of today, no randomized trial has demonstrated a beneficial effect of any drug on ADHF prognosis. Thus, there is still a urgent need for better therapies. Several drug classes have been developed to correct or mitigate disordered pathways and, thereby, preserve and protect myocytes. Such are natriuretic peptides, modulators of soluble and particulate guanylate cyclase, the vasoactive peptide serelaxin, HNO prodrugs, etc.

Prof. Mitrovic will discuss the role of vasoactive drugs in the management of ADHF.

Wednesday, 24.05.2017
12:00 – 13:00h
Bibliothek at DHZB
Augustenburger Platz 1, Berlin